Overview

Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy

Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
Medication abortion is a way of ending a pregnancy using pills. The current FDA-approved regimen for medication abortion uses mifepristone and misoprostol. This study is testing whether a different medication, atorvastatin, followed by misoprostol, can be used to end a pregnancy. Participants at 35-49 days of pregnancy will receive an oral dose of atorvastatin (80 mg) to swallow at the clinic as well as taking atorvastatin (80 mg) daily for six additional days, with a return to clinic on day 8 after initial visit to take a dose of misoprostol (800 mcg). Additionally, follow-up visits will occur on approximately days 3, 8 and 11 for a clinician to perform an ultrasound to see if the abortion is complete.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Utah
Collaborator:
Grand Challenges Canada
Treatments:
Atorvastatin
Misoprostol